View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Corbion reports the progress of its € 10 million share buyback program...

Corbion reports the progress of its € 10 million share buyback program 1 September – 5 September 2025 Corbion hereby reports the transaction details related to its € 10 million share buyback program announced on 1 September 2025. During the week of 1 September up to and including 5 September 2025 a total of 83,962 shares were repurchased at an average price of €17.3463 for a total amount of €1,456,431.48. To date, the total consideration for shares repurchased amounts to €1,456,431.48 representing 14.56% of the overall share buyback program. Corbion publishes on a weekly basis every Mond...

 PRESS RELEASE

Inventiva to Participate in Upcoming September Investor Conferences

Inventiva to Participate in Upcoming September Investor Conferences Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in the following upcoming investor events:  H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday, September 9, 2025Time of the fi...

 PRESS RELEASE

Inventiva annonce sa participation à plusieurs conférences investisseu...

Inventiva annonce sa participation à plusieurs conférences investisseurs en septembre Daix (France), New York City (New York, Etats-Unis), le 4 septembre 2025 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que son équipe de direction participera aux conférences investisseurs suivantes :H.C. Wainwright 27th Annual Global Investment Conference Date : Mardi 9 septembre 2025Heur...

Hilde Van Boxstael ... (+7)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Hoste

Morning Notes : CRBN NA, DIE BB, DSFIR NA, UCB BB, EKOP BB, CTPNV NA, ...

: CRBN NA, DIE BB, DSFIR NA, UCB BB, EKOP BB, CTPNV NA, JDEP NA

 PRESS RELEASE

Corbion announces share buyback program to cover commitments under the...

Corbion announces share buyback program to cover commitments under the long-term employee incentive plan Corbion announces a share buyback program under which it plans to repurchase ordinary shares of Corbion N.V. for a maximum total amount of € 10 million and a maximum of 580.383 shares (based on the closing price of the Corbion ordinary share on Euronext Amsterdam on August 29, 2025). The share buyback program will be executed as from 1 September 2025, and will run until 30 November 2025 (or earlier if the maximum total amount or number of shares have been repurchased before that date). ...

Hilde Van Boxstael ... (+6)
  • Hilde Van Boxstael
  • Kristof Samoy
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Wim Lewi
Guy Sips ... (+6)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Lewi

Morning Notes : AGS BB, AGFB BB, IVA FP, RET BB, TWEKA NA, VAN BB, NXF...

: AGS BB, AGFB BB, IVA FP, RET BB, TWEKA NA, VAN BB, NXFIL NA, IMCD NA

Jacob Mekhael
  • Jacob Mekhael

Inventiva A MASH turnaround story with big upside potential

Inventiva's lanifibranor is the next in line candidate in MASH, with its phase 3 (NATiV3) trial now fully recruited, locking in a topline readout for 2H26. The program is de-risked by a robust phase 2b, showing competitive fibrosis response rates and strong HbA1c reduction— a key differentiator for the large MASH + T2D population. With oral dosing and clean safety, lanifibranor is well-positioned to capture a meaningful share of the validated MASH commercial opportunity. A € 348m structured fina...

 PRESS RELEASE

Corbion and Kuehnle AgroSystems join forces to develop natural Astaxan...

Corbion and Kuehnle AgroSystems join forces to develop natural Astaxanthin from algae fermentation Corbion, the Amsterdam-based global leader in sustainable ingredients, and US-based biotech company Kuehnle AgroSystems (KAS) have entered into a strategic partnership to develop and commercialize a high-quality, natural astaxanthin derived from non-GMO heterotrophic algae. Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms, including microalgae, salmon, and shrimp. It is widely recognized both for its human health benefits and as a key ...

 PRESS RELEASE

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45t...

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference Daix (France), New York City (New York, United States), August 11, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that Jason Campagna, MD, PhD, President of R&D and Chief Medical Officer, and David Nikodem, PhD, Vice President of US Operations will participate in a fireside chat at the Canacc...

 PRESS RELEASE

Inventiva Participera à la « Canaccord Genuity 45th Annual Growth Conf...

Inventiva Participera à la « Canaccord Genuity 45th Annual Growth Conference » Daix (France), New York City (New York, Etats-Unis), le 11 aout 2025 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd'hui que Jason Campagna, MD, PhD, Président de la R&D et Directeur Médical, et David Nikodem, PhD, Vice-Président des opérations aux États-Unis, participeront à un « fireside chat » lors d...

Steven Gould
  • Steven Gould
Steven Gould
  • Steven Gould
 PRESS RELEASE

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvr...

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Keple...

 PRESS RELEASE

Bilan semestriel du contrat de liquidité de la société Inventiva concl...

Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), New York (New York, Etats-Unis), le 31 juillet 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite non alcoolique ("NASH") et d’autres maladies avec un besoin médical non satisfait significatif, annonce aujourd’hui le bilan semestriel de son contrat de liquidité conclu avec Kepler Cheuvreux. Au titre du contrat de...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

AB InBev: 2Q25 results. Air France-KLM: Nice beat, let's see how FY25 finishes. AMG: Uptrend continues in 2Q25 with 23% EBITDA beat and guidance up to +US$200m. Aperam: Slight 2Q25 EBITDA beat, 3Q25 seen down QoQ. Arcadis: EBITA margin held up well in 2Q25, order intake mixed. Ayvens: 2Q25 results. Azelis: Soft but largely in-line 2Q25 with EMEA offsetting weaker APAC. Bekaert: 1H25 miss and lowered outlook to result in c.5% consensus downside. Corbion: Taking it to the wire. dsm...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch